[go: up one dir, main page]

WO1999037777A3 - Differentiation-associated sequences and methods of use therefor - Google Patents

Differentiation-associated sequences and methods of use therefor Download PDF

Info

Publication number
WO1999037777A3
WO1999037777A3 PCT/US1999/001624 US9901624W WO9937777A3 WO 1999037777 A3 WO1999037777 A3 WO 1999037777A3 US 9901624 W US9901624 W US 9901624W WO 9937777 A3 WO9937777 A3 WO 9937777A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
differentiation
polypeptides
polynucleotides
cancer therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/001624
Other languages
French (fr)
Other versions
WO1999037777A2 (en
Inventor
Fei Huang
Paul B Fisher
Neil I Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENQUEST Inc
Original Assignee
GENQUEST Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENQUEST Inc filed Critical GENQUEST Inc
Priority to AU23433/99A priority Critical patent/AU2343399A/en
Publication of WO1999037777A2 publication Critical patent/WO1999037777A2/en
Publication of WO1999037777A3 publication Critical patent/WO1999037777A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compositions and methods are provided for inhibiting cell growth, inducing terminal differentiation and cancer therapy. The compounds provided are polypeptides and polynucleotides associated with terminal differentiation and growth arrest, as well as polynucleotides that encode such polypeptides. Vaccines and pharmaceutical compositions comprising such compounds are also provided and may be used, for example, for cancer therapy. Such molecules may also be used, for example, to identify agents that may be used in vaccines and pharmaceutical compositions for cancer therapy. The polypeptides and polynucleotides provided herein may also be used as markers for diagnosing and monitoring the progression of a cancer in a patient.
PCT/US1999/001624 1998-01-26 1999-01-26 Differentiation-associated sequences and methods of use therefor Ceased WO1999037777A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23433/99A AU2343399A (en) 1998-01-26 1999-01-26 Differentiation-associated sequences and methods of use therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7252498P 1998-01-26 1998-01-26
US60/072,524 1998-01-26
US8465098P 1998-05-07 1998-05-07
US60/084,650 1998-05-07

Publications (2)

Publication Number Publication Date
WO1999037777A2 WO1999037777A2 (en) 1999-07-29
WO1999037777A3 true WO1999037777A3 (en) 1999-09-30

Family

ID=26753455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001624 Ceased WO1999037777A2 (en) 1998-01-26 1999-01-26 Differentiation-associated sequences and methods of use therefor

Country Status (2)

Country Link
AU (1) AU2343399A (en)
WO (1) WO1999037777A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011986A1 (en) * 1993-10-27 1995-05-04 The Trustees Of Columbia University In The City Of New York METHOD FOR GENERATING A SUBTRACTED cDNA LIBRARY AND USES OF THE GENERATED LIBRARY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011986A1 (en) * 1993-10-27 1995-05-04 The Trustees Of Columbia University In The City Of New York METHOD FOR GENERATING A SUBTRACTED cDNA LIBRARY AND USES OF THE GENERATED LIBRARY

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "Cloning a cDNA from human NK/T cells which codes for a protein with high proline content", BIOCHIM BIOPHYS ACTA, vol. 1264, no. 1, 17 October 1995 (1995-10-17), pages 19 - 22, XP002108017 *
DATABASE EMEST 15 E.M.B.L. Databases; 4 June 1997 (1997-06-04), HILLIER L ET AL: "Homo sapiens cDNA clone 758808 5' similar to TR:G476095 B4-2 protein", XP002108018 *
H JIANG AND P B FISHER: "Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells", MOLECULAR AND CELLULAR DIFFERENTIATION, vol. 3, no. 1, 1 July 1993 (1993-07-01), pages 285 - 289, XP002078760 *
H JIANG ET AL: "A molecular definition of terminal cell differentiation in human melanoma cells", MOLECULAR AND CELLULAR DIFFERENTIATION, vol. 2, no. 3, 1 July 1994 (1994-07-01), pages 221 - 239, XP002078944 *

Also Published As

Publication number Publication date
WO1999037777A2 (en) 1999-07-29
AU2343399A (en) 1999-08-09

Similar Documents

Publication Publication Date Title
EP1876241A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
EA200000759A1 (en) DERIVATIVES 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOLA
HUP0203035A2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
EP1420009A3 (en) Novel amino acid derivatives with improved multi-drug resistance activity
SE9502167D0 (en) Insulin analog formulations
WO1996034953A3 (en) Cd16-ii variants
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
IL148870A0 (en) 2'-substituted 1, 1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds
ITRM920412A1 (en) HETEROPROSTANOIDS, PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC USE.
WO2000066528A3 (en) Quinones for treatment of diseases
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
DK0572688T3 (en) Peptides, with organ-protective activity, method for their preparation and their use in therapy
WO2001079276A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
BG101126A (en) The use of muramylpeptide compounds
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
WO1999037774A3 (en) Differentiation-associated sequences and methods of use therefor
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
RU96119472A (en) OPHTHALMIC IRRIGATION SOLUTION
FI871545A7 (en) A method for preparing a synergistic mixture for use in the treatment of cancer, comprising interleukin-2 and/or interferon-α and tumor necrosis factor.
WO1999037777A3 (en) Differentiation-associated sequences and methods of use therefor
WO1999060124A3 (en) Differentiation-associated sequences and methods of use therefor
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
WO1999030670A3 (en) Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
ITRM930154A0 (en) USE OF TERBINAFINE FOR THE THERAPEUTIC TREATMENT OF PNEUMOCYSTOSIS.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase